Nagata, Jason M. http://orcid.org/0000-0002-6541-0604
Compte, Emilio J.
McGuire, F. Hunter
Lavender, Jason M.
Brown, Tiffany A.
Murray, Stuart B.
Flentje, Annesa
Capriotti, Matthew R.
Lubensky, Micah E.
Obedin-Maliver, Juno
Lunn, Mitchell R.
Funding for this research was provided by:
American Heart Association (CDA34760281)
National Institutes of Health (K23 MH115184)
National Institute on Drug Abuse (K23DA039800)
Tourette Association of America
American Academy of Neurology
Patient-Centered Outcomes Research Institute (PPRN‐1501‐26848)
National Institute of Diabetes and Digestive and Kidney Diseases (K12DK111028)
Article History
Received: 12 April 2021
Accepted: 2 July 2021
First Online: 14 July 2021
Declarations
:
: The University of California, San Francisco and Stanford University Institutional Review Boards approved this study (#16–21213). Written informed consent was obtained from all participants.
: Not applicable.
: Dr. Juno Obedin-Maliver has consulted for Sage Therapeutics (5/2017) in a one-day advisory board, Ibis Reproductive Health (a non-for-profit research group; 3/2017–5/2018, 2020-present), Folx, Inc. (2020 – present), and Hims Inc. (2019 - present). Dr. Lunn has consulted for Hims Inc. (2019 - present) and Folx, Inc. (2020). None of these roles present a conflict of interest with this work as described here. The other authors have no conflicts of interest to report.